Hepcidin in the management of patients with mild non-hemochromatotic iron overload: Fact or fiction?

Journal of Hepatology

Volumn 49, Issue 5, 2008, Pages 680-685

  Swinkels, Dorine W ^a   Drenth, Joost P H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; HEPCIDIN;

ALCOHOL CONSUMPTION; CLINICAL FEATURE; DISEASE ASSOCIATION; EDITORIAL; HEPATITIS C; HORMONE DETERMINATION; HUMAN; IRON OVERLOAD; LIVER DISEASE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL;

ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; HUMANS; IRON OVERLOAD; MODELS, BIOLOGICAL; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 53249121484     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.08.004     Document Type: Editorial

References (67)

1. Fernandez-Real J.M., Lopez-Bermejo A., and Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 51 (2002) 2348-2354
2. Wrede C.E., Buettner R., Bollheimer L.C., Scholmerich J., Palitzsch K.D., and Hellerbrand C. Association between serum ferritin and the insulin resistance syndrome in a representative population. Eur J Endocrinol 154 (2006) 333-340
3. Moirand R., Mortaji A.M., Loreal O., Paillard F., Brissot P., and Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet 349 (1997) 95-97
4. Bozzini C., Girelli D., Olivieri O., Martinelli N., Bassi A., De Matteis G., et al. Prevalence of body iron excess in the metabolic syndrome. Diabetes Care 28 (2005) 2061-2063
5. Turlin B., Mendler M.H., Moirand R., Guyader D., Guillygomarc'h A., and Deugnier Y. Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients. Am J Clin Pathol 116 (2001) 263-270
6. Bacon B.R. Iron and hepatitis C. Gut 41 (2007) 127-128
7. Purohit V., Russo D., and Salin M. Role of iron in alcoholic liver disease: introduction and summary of the symposium. Alcohol 30 (2003) 93-97
8. Mendler M.H., Turlin B., Moirand R., Jouanolle A.M., Sapey T., Guyader D., et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 117 (1999) 1155-1163
9. George D.K., Powell L.W., and Losowsky M.S. The haemochromatosis gene: a co-factor for chronic liver diseases?. J Gastroenterol Hepatol 14 (1999) 745-749
10. Bonkovsky H.L., Lambrecht R.W., and Shan Y. Iron as a co-morbid factor in nonhemochromatotic liver disease. Alcohol 30 (2003) 137-144
11. Bonkovsky H.L., Jawaid Q., Tortorelli K., LeClair P., Cobb J., Lambrecht R.W., et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 31 (1999) 421-429
12. Chitturi S., Weltman M., Farrell G.C., McDonald D., Kench J., Liddle C., et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 36 (2002) 142-149
13. Snover D.C. Hepatitis C, iron, and hemochromatosis gene mutations A meaningful relationship or simple cohabitation?. Am J Clin Pathol 113 (2000) 475-478
14. Pietrangelo A. Hemochromatosis gene modifies course of hepatitis C viral infection. Gastroenterology 124 (2003) 1509-1523
15. Piperno A., Vergani A., Malosio I., Parma L., Fossati L., Ricci A., et al. Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations. Hepatology 28 (1998) 1105-1109
16. Grove J., Daly A.K., Burt A.D., Guzail M., James O.F., Bassendine M.F., et al. Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease. Gut 43 (1998) 262-266
17. Peyssonnaux C., Zinkernagel A.S., Datta V., Lauth X., Johnson R.S., and Nizet V. TLR4-dependent hepcidin expression by myeloid cells in response to bacterial pathogens. Blood 107 (2006) 3727-3732
18. Bekri S., Gual P., Anty R., Luciani N., Dahman M., Ramesh B., et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 131 (2006) 788-796
19. Pajukanta P., Lilja H.E., Sinsheimer J.S., Cantor R.M., Lusis A.J., Gentile M., et al. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet 36 (2004) 371-376
20. Bayele H.K., McArdle H., and Srai S.K. Cis and trans regulation of hepcidin expression by upstream stimulatory factor. Blood 108 (2006) 4237-4245
21. Weinstein D.A., Roy C.N., Fleming M.D., Loda M.F., Wolfsdorf J.I., and Andrews N.C. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 100 (2002) 3776-3781
22. Piperno A., Trombini P., Gelosa M., Mauri V., Pecci V., Vergani A., et al. Increased serum ferritin is common in men with essential hypertension. J Hypertens 20 (2002) 1513-1518
23. Rossi E., Bulsara M.K., Olynyk J.K., Cullen D.J., Summerville L., and Powell L.W. Effect of hemochromatosis genotype and lifestyle factors on iron and red cell indices in a community population. Clin Chem 47 (2001) 202-208
24. Brunt E.M. Pathology of hepatic iron overload. Semin Liver Dis 25 (2005) 392-401
25. George D.K., Goldwurm S., MacDonald G.A., Cowley L.L., Walker N.I., Ward P.J., et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 114 (1998) 311-318
26. Fargion S., Mattioli M., Fracanzani A.L., Sampietro M., Tavazzi D., Fociani P., et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 96 (2001) 2448-2455
27. Fujita N., Horiike S., Sugimoto R., Tanaka H., Iwasa M., Kobayashi Y., et al. Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients. Free Radic Biol Med 42 (2007) 353-362
28. Furutani T., Hino K., Okuda M., Gondo T., Nishina S., Kitase A., et al. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 130 (2006) 2087-2098
29. Diwakaran H.H., Befeler A.S., Britton R.S., Brunt E.M., and Bacon B.R. Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. J Hepatol 36 (2002) 687-691
30. Nahon P., Sutton A., Rufat P., Ziol M., Thabut G., Schischmanoff P.O., et al. Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology 134 (2008) 102-110
31. Raynard B., Balian A., Fallik D., Capron F., Bedossa P., Chaput J.C., et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 35 (2002) 635-638
32. Bugianesi E., Manzini P., D'Antico S., Vanni E., Longo F., Leone N., et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39 (2004) 179-187
33. Younossi Z.M., Gramlich T., Bacon B.R., Matteoni C.A., Boparai N., O'Neill R., et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 30 (1999) 847-850
34. Barisani D., Pelucchi S., Mariani R., Galimberti S., Trombini P., Fumagalli D., et al. Hepcidin and iron-related gene expression in subjects with dysmetabolic hepatic iron overload. J Hepatol 49 (2008) 123-133
35. Aigner E., Theurl I., Theurl M., Lederer D., Haufe H., Dietze O., et al. Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am J Clin Nutr 87 (2008) 1374-1383
36. Fujita N., Sugimoto R., Motonishi R., Tomosugi N., Tanaka H., Takeo M., et al. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. J Hepatol 49 (2008) 702-710
37. Pigeon C., Ilyin G., Courselaud B., Leroyer P., Turlin B., Brissot P., et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 276 (2001) 7811-7819
38. Kemna E.H., Tjalsma H., Podust V.N., and Swinkels D.W. Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin Chem 53 (2007) 620-628
39. Park C.H., Valore E.V., Waring A.J., and Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276 (2001) 7806-7810
40. Hunter H.N., Fulton D.B., Ganz T., and Vogel H.J. The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis. J Biol Chem 277 (2002) 37597-37603
41. Kemna E.H., Kartikasari A.E., van Tits L.J., Pickkers P., Tjalsma H., and Swinkels D.W. Regulation of hepcidin: Insights from biochemical analyses on human serum samples. Blood Cells Mol Dis 40 (2008) 339-346
42. Kemna E., Pickkers P., Nemeth E., van der Hoeven H., and Swinkels D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 106 (2005) 1864-1866
43. Brookes M.J., Sharma N.K., Tselepis C., and Iqbal T.H. Serum pro-hepcidin: measuring active hepcidin or a non-functional precursor?. Gut 54 (2005) 169-170
44. Roe M.A., Spinks C., Heath A.L., Harvey L.J., Foxall R., Wimperis J., et al. Serum prohepcidin concentration: no association with iron absorption in healthy men; and no relationship with iron status in men carrying HFE mutations, hereditary haemochromatosis patients undergoing phlebotomy treatment, or pregnant women. Br J Nutr 97 (2007) 544-549
45. Nemeth E., Valore E.V., Territo M., Schiller G., Lichtenstein A., and Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101 (2003) 2461-2463
46. Ganz T. Hepcidin and its role in regulating systemic iron metabolism. Hematol Am Soc Hematol Edu Prog 507 (2006) 29-35
47. Tomosugi N., Kawabata H., Wakatabe R., Higuchi M., Yamaya H., Umehara H., et al. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 108 (2006) 1381-1387
48. Murphy A.T., Witcher D.R., Luan P., and Wroblewski V.J. Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry. Blood 110 (2007) 1048-1054
49. Murao N., Ishigai M., Yasuno H., Shimonaka Y., and Aso Y. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun Mass Spectrom 21 (2007) 4033-4038
50. Swinkels D.W., Girelli D., Laarakkers C., Kroot J., Camprostrini N., Kemna E.H., et al. Advances in quantitative hepcidin measurements by time of flight mass spectrometry. PLoS ONE 3 (2008) e2706
51. van Dijk BA, Laarakkers CM, Klaver SM, Jacobs EM, van Tits LJ, Janssen MC, et al. Serum hepcidin levels are innately low in HFE-related haemochromatosis but differ between C282Y-homozygotes with elevated and normal ferritin levels. Br J Haematol, 2008 June 13. [Epub ahead of print] PMID: 18557745 [PubMed - as supplied by publisher].
52. Detivaud L., Nemeth E., Boudjema K., Turlin B., Troadec M.B., Leroyer P., et al. Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels and hepatic function. Blood 106 (2005) 746-748
53. Kemna E.H., Tjalsma H., Willems H.L., and Swinkels D.W. Hepcidin: from discovery to differential diagnosis. Haematologica 93 (2008) 90-97
54. Kulaksiz H., Theilig F., Bachmann S., Gehrke S.G., Rost D., Janetzko A., et al. The iron-regulatory peptide hormone hepcidin: expression and cellular localization in the mammalian kidney. J Endocrinol 184 (2005) 361-370
55. Chung B., Matak P., McKie A.T., and Sharp P. Leptin increases the expression of the iron regulatory hormone hepcidin in HuH7 human hepatoma cells. J Nutr 137 (2007) 2366-2370
56. Oates P.S. The relevance of the intestinal crypt and enterocyte in regulating iron absorption. Pflugers Arch 455 (2007) 201-213
57. Chaston T., Chung B., Mascarenhas M., Marks J., Patel B., Srai S.K., et al. Evidence for differential effects of hepcidin in macrophages and intestinal epithelial cells. Gut 57 (2008) 374-382
58. Papanikolaou G., Tzilianos M., Christakis J.I., Bogdanos D., Tsimirika K., MacFarlane J., et al. Hepcidin in iron overload disorders. Blood 105 (2005) 4103-4105
59. Di Bisceglie A.M., Axiotis C.A., Hoofnagle J.H., and Bacon B.R. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 102 (1992) 2108-2113
60. Montosi G., Corradini E., Garuti C., Barelli S., Recalcati S., Cairo G., et al. Kupffer cells and macrophages are not required for hepatic hepcidin activation during iron overload. Hepatology 41 (2005) 545-552
61. Lou D.Q., Lesbordes J.C., Nicolas G., Viatte L., Bennoun M., Van Rooijen N., et al. Iron- and inflammation-induced hepcidin gene expression in mice is not mediated by Kupffer cells in vivo. Hepatology 41 (2005) 1056-1064
62. Theurl I., Theurl M., Seifert M., Mair S., Nairz M., Rumpold H., et al. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood 111 (2008) 2392-2399
63. Ludwiczek S., Aigner E., Theurl I., and Weiss G. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 101 (2003) 4148-4154
64. Harrison-Findik D.D., Schafer D., Klein E., Timchenko N.A., Kulaksiz H., Clemens D., et al. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J Biol Chem 281 (2006) 22974-22982
65. Bridle K., Cheung T.K., Murphy T., Walters M., Anderson G., Crawford D.G., et al. Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease. Alcohol Clin Exp Res 30 (2006) 106-112
66. Harrison-Findik D.D., Klein E., Crist C., Evans J., Timchenko N., and Gollan J. Iron-mediated regulation of liver hepcidin expression in rats and mice is abolished by alcohol. Hepatology 46 (2007) 1979-1985
67. Nishina S., Hino K., Korenaga M., Vecchi C., Pietrangelo A., Mizukami Y., et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 134 (2008) 226-238